EGFR and interstitial lung disease: Although interstitial lung disease is rare, interstitial lung disease has been reported to occur after the use of TKI for lung cancer, and the onset is often rapid; Interstitial lung disease occurred in 2.2% to 4.5% of METex14-jumping NSCLC patients treated with capmatinib, tepotinib, or crizotinib, and 0.3% to 0.5% died.[8] Whether EGFR-TKI combined with MET-TKI increases the incidence of interstitial lung disease needs more further study.